[Effect of intra-operative low-dose infusion of landiolol hydrochloride on post-operative atrial fibrillation after off-pump coronary artery bypass grafting].
The aim of this study was to evaluate the effect of intra-operative low-dose infusion of landiolol hydrochloride, a novel ultra-short acting beta-1 adrenergic receptor antagonist, on post-operative atrial fibrillation after off-pump coronary artery bypass grafting (OPCAB). Ninety-six patients who had undergone OPCAB were retrospectively analyzed. A landiolol group (L-group: n= 59) was compared with a control group (C-group : n= 37); the patients in the L-group were given low-dose (4.7+/- 4.3 microg/kg/min) landiolol intravenously during OPCAB. Results : Postoperative atrial fibrillation occurred in 37.8% (14/37) of C-group and 18.6% (11/59) of L-group (p = 0.037). No side effect such as profound hypotension or bradycardia was noticed during the infusion of landiolol hydrochloride. Intra-operative low-dose infusion of landiolol hydrochloride decreases the incidence of postoperative atrial fibrillation after OPCAB.